Humacyte, Inc. (HUMAW) — 10-Q Filings
All 10-Q filings from Humacyte, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Humacyte Narrows Q3 Loss, Boosted by Revenue and Liability Adjustments
— Nov 12, 2025 Risk: high
Humacyte, Inc. (HUMAW) reported a net loss of $17.5 million for the three months ended September 30, 2025, a significant improvement from the $39.2 million net -
Humacyte Reports No Revenue, Relies on Capital Raises for Clinical Progress
— Aug 11, 2025 Risk: high
Humacyte, Inc. reported no product revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remains in t -
Humacyte Q1 2025 Revenue Flat, Expenses Stable
— May 13, 2025 Risk: medium
Humacyte, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue of $0.16 million for the first quarter of 2025, a decrease from -
Humacyte Reports Q3 2024 Losses, Cash Reserves Dip
— Nov 8, 2024 Risk: high
Humacyte, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss of $45.5 million for the three months ended September 30 -
Humacyte Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Humacyte, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. K -
Humacyte, Inc. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: medium
Humacyte, Inc. (HUMAW) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Humacyte, Inc. filed a 10-Q report for the period ending March 31, 2024. Th
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX